IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures
Long, Anhua1,2; Zhang, Lihai1; Zhang, Yingze3; Jiang, Baoguo4; Mao, Zhi1; Li, Hongda2; Zhang, Shanbao2; Xie, Zongyan2; Tang, Peifu1
关键词Deep vein thrombosis Venous thromboembolism Major bleeding events Thromboprophylaxis Rivaroxaban Low-molecular-weight heparin
刊名JOURNAL OF THROMBOSIS AND THROMBOLYSIS
2014-10-01
DOI10.1007/s11239-013-1046-1
38期:3页:299-305
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Peripheral Vascular Disease
研究领域[WOS]Hematology ; Cardiovascular System & Cardiology
关键词[WOS]TOTAL KNEE ARTHROPLASTY ; DEEP-VEIN THROMBOSIS ; VENOUS THROMBOEMBOLISM ; ORTHOPEDIC-SURGERY ; HIP-ARTHROPLASTY ; THROMBOPROPHYLAXIS ; ENOXAPARIN ; TRIAL
英文摘要

Thromboprophylaxis with rivaroxaban has proved effective and safe in patients undergoing hip and knee replacement surgery. As it is unclear whether it is also effective and safe in fracture patients, the aim of the present study was to evaluate the efficacy and safety of rivaroxaban in patients with lower limb fractures. We performed a retrospective cohort study of 2,050 consecutive patients treated for lower limb fractures at our trauma center, comparing rates of venous thromboembolism (VTE), bleeding and surgical complications, and the length of hospital stay for 608 patients who received rivaroxaban and 717 who received a low-molecular-weight heparin (LMWH). Rates of symptomatic VTE were 4.9 and 8.6 % in the rivaroxaban and LMWH groups, respectively (p = 0.008), and distal VTE rates were 1.8 and 5.7 %, respectively (p = 0.036). The incidence of major bleeding events in the rivaroxaban group was also lower than in the LMWH group (0.2 vs 0.6 %), but the difference between the groups was not statistically significant. The mean length of hospital stay was significantly shorter in the rivaroxaban group (12.2 vs 13.1 days, respectively; p = 0.016). This retrospective cohort study is the first report documenting the efficacy and safety of rivaroxaban in patients with lower extremity fractures. In comparison with LMWH, rivaroxaban reduced the incidence of VTE by 45 % without increasing the risk of bleeding. However, prospective, randomized controlled trials comparing rivaroxaban and LMWH are needed to confirm our findings.

语种英语
WOS记录号WOS:000341085300003
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66212
专题北京大学第二临床医学院
北京大学第二临床医学院_党委院长办公室
作者单位1.Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing 100853, Peoples R China
2.Hebei Med Univ, Hosp 1, Dept Orthoped, Shijiazhuang 050031, Hebei Province, Peoples R China
3.Nankai Univ, Sch Med, Tianjin 300071, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Long, Anhua,Zhang, Lihai,Zhang, Yingze,et al. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS,2014,38(3):299-305.
APA Long, Anhua.,Zhang, Lihai.,Zhang, Yingze.,Jiang, Baoguo.,Mao, Zhi.,...&Tang, Peifu.(2014).Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.JOURNAL OF THROMBOSIS AND THROMBOLYSIS,38(3),299-305.
MLA Long, Anhua,et al."Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures".JOURNAL OF THROMBOSIS AND THROMBOLYSIS 38.3(2014):299-305.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Long, Anhua]的文章
[Zhang, Lihai]的文章
[Zhang, Yingze]的文章
百度学术
百度学术中相似的文章
[Long, Anhua]的文章
[Zhang, Lihai]的文章
[Zhang, Yingze]的文章
必应学术
必应学术中相似的文章
[Long, Anhua]的文章
[Zhang, Lihai]的文章
[Zhang, Yingze]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。